2021/12/04 更新

写真a

マツモト ヨシフミ
松本 吉史
MATSUMOTO Yoshifumi
所属
医歯学総合病院 腫瘍センター 特任准教授
職名
特任准教授
外部リンク

学位

  • 博士(医学) ( 2015年3月   新潟大学 )

  • 学士(医学) ( 2009年3月   弘前大学 )

  • 学士(農学) ( 2002年3月   東京農工大学 )

  • 修士(農学) ( 2002年3月   東京農工大学 )

研究分野

  • ライフサイエンス / 血液、腫瘍内科学

経歴(researchmap)

  • 新潟大学医歯学総合病院   腫瘍センター   特任准教授

    2020年10月 - 現在

      詳細を見る

    国名:日本国

    researchmap

  • 新潟大学   医歯学総合研究科   特任講師

    2017年10月 - 現在

      詳細を見る

  • 新潟大学   医歯学総合病院 腫瘍センター   特任助教

    2015年4月 - 2017年9月

      詳細を見る

経歴

  • 新潟大学   医歯学総合病院 腫瘍センター   特任准教授

    2020年10月 - 現在

  • 新潟大学   医歯学総合研究科   特任講師

    2017年10月 - 2020年3月

  • 新潟大学   医歯学総合病院 腫瘍センター   特任助教

    2015年4月 - 2017年9月

 

論文

  • Analysis of Pharmacokinetics in the Cochlea of the Inner Ear. 国際誌

    Seishiro Sawamura, Genki Ogata, Kai Asai, Olga Razvina, Takeru Ota, Qi Zhang, Sasya Madhurantakam, Koei Akiyama, Daisuke Ino, Sho Kanzaki, Takuro Saiki, Yoshifumi Matsumoto, Masato Moriyama, Yasuo Saijo, Arata Horii, Yasuaki Einaga, Hiroshi Hibino

    Frontiers in pharmacology   12   633505 - 633505   2021年

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Hearing loss affects >5% of the global population and therefore, has a great social and clinical impact. Sensorineural hearing loss, which can be caused by different factors, such as acoustic trauma, aging, and administration of certain classes of drugs, stems primarily from a dysfunction of the cochlea in the inner ear. Few therapeutic strategies against sensorineural hearing loss are available. To develop effective treatments for this disease, it is crucial to precisely determine the behavior of ototoxic and therapeutic agents in the microenvironment of the cochlea in live animals. Since the 1980s, a number of studies have addressed this issue by different methodologies. However, there is much less information on pharmacokinetics in the cochlea than that in other organs; the delay in ontological pharmacology is likely due to technical difficulties with accessing the cochlea, a tiny organ that is encased with a bony wall and has a fine and complicated internal structure. In this review, we not only summarize the observations and insights obtained in classic and recent studies on pharmacokinetics in the cochlea but also describe relevant analytical techniques, with their strengths, limitations, and prospects.

    DOI: 10.3389/fphar.2021.633505

    PubMed

    researchmap

  • Age-Based Comparison of Hematological Toxicity in Patients with Lung Cancer 国際誌

    Yuki Sakai, Qiliang Zhou, Yoshifumi Matsumoto, Takuro Saiki, Masato Moriyama, Akira Toyama, Yasuo Saijo

    Oncology   1 - 8   2020年8月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:S. Karger AG  

    INTRODUCTION: Because of the increasing age of the general population, there is an increasing number of older patients with lung cancer. Cancer chemotherapy often causes severe hematological toxicity in older patients. OBJECTIVE: This study aimed to explore the risk factors affecting the hematological toxicity of cytotoxic anticancer drugs in patients with lung cancer. METHODS: Data were retrospectively collected from 194 patients with lung cancer at Niigata University Medical and Dental Hospital, Japan, between April 2011 and March 2016, when the patients underwent their first round of cytotoxic chemotherapy. The patients were divided into three groups on the basis of age: <65, 65-74, and ≥75 years. Physiological functions and laboratory data before treatment, as well as hematological adverse events following chemotherapy, were compared among the groups. RESULTS: Patients aged ≥75 years were significantly more likely to experience grade 3 or 4 neutropenia, compared with patients aged <65 years. However, there were no differences in the incidence of anemia or thrombocytopenia among the age groups. The frequency of febrile neutropenia tended to increase with age. Multivariate analysis showed that age ≥75 years, male sex, and a performance status of ≥2 were independent factors for grade 3 or 4 neutropenia. Patients with 2 or 3 of these factors had a significantly higher frequency of neutropenia, compared with patients who had 0 or 1 of these factors. CONCLUSION: We found that age ≥75 years, male sex, and a performance status of ≥2 were independent risk factors for grade 3 or 4 neutropenia.

    DOI: 10.1159/000507864

    PubMed

    researchmap

  • Treatments and outcomes of older patients with esophageal cancer: Comparison with younger patients. 査読

    Matsumoto Y, Kimura K, Zhou Q, Sasaki K, Saiki T, Moriyama M, Saijo Y

    Molecular and clinical oncology   11 ( 4 )   383 - 389   2019年10月

  • Treatment of Gastric and Gastroesophageal Cancer Patients with Hemodialysis by CapeOX. 査読

    Sasaki K, Zhou Q, Matsumoto Y, Saiki T, Moriyama M, Saijo Y

    Internal medicine (Tokyo, Japan)   2019年6月

  • Cancers among adolescents and young adults at one institution in Japan. 査読

    Kamimura K, Matsumoto Y, Zhou Q, Moriyama M, Saijo Y

    Oncology letters   16 ( 6 )   7212 - 7222   2018年12月

  • Trachea Engineering Using a Centrifugation Method and Mouse Induced Pluripotent Stem Cells. 査読

    Zhou Q, Ye X, Ran Q, Kitahara A, Matsumoto Y, Moriyama M, Ajioka Y, Saijo Y

    Tissue Eng Part C Methods.   2018年8月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    researchmap

  • The Prognostic Nutrition Index Predicts the Development of Hematological Toxicities in and the Prognosis of Esophageal Cancer Patients Treated with Cisplatin Plus 5-Fluorouracil Chemotherapy 査読

    Yoshifumi Matsumoto, Qiliang Zhou, Kensuke Kamimura, Masato Moriyama, Yasuo Saijo

    Nutrition and Cancer   70 ( 3 )   447 - 452   2018年4月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Routledge  

    The prognostic nutrition index (PNI), calculated based on serum albumin and lymphocyte counts, predicts the prognosis of several cancers, including operated esophageal cancers. In this study, we determined whether PNI could predict the occurrence of severe adverse events by chemotherapy and chemoradiotherapy, and overall survival in esophageal cancer. We collected data from 191 patients with esophageal cancer treated with at least one course of cisplatin and 5-fluorouracil from 2005 to 2016. We compared the incidences of severe adverse events and overall survival between a high- and a low-PNI group. The optimal cut-off value of the Onodera PNI was 43.2. Patients with low PNIs suffered more frequent severe adverse events than did those with high PNIs, and the latter patients survived longer. The PNI was independently prognostic of overall survival and stage. The PNI predicted the development of severe adverse events caused by chemotherapy or chemoradiotherapy, and overall survival, in esophageal cancer patients.

    DOI: 10.1080/01635581.2018.1445765

    Scopus

    researchmap

  • Inhibition of Glutaminolysis Inhibits Cell Growth via Down-regulating Mtorc1 Signaling in Lung Squamous Cell Carcinoma 査読

    Xulu Ye, Qiliang Zhou, Yoshifumi Matsumoto, Masato Moriyama, Shun Kageyama, Masaaki Komatsu, Seijiro Satoh, Masanori Tsuchida, Yasuo Saijo

    ANTICANCER RESEARCH   36 ( 11 )   6021 - 6029   2016年11月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:INT INST ANTICANCER RESEARCH  

    Background/Aim: Inhibition of glutaminolysis has been reported as a promising therapeutic strategy to target several solid carcinomas. We aimed to investigate the effects of glutaminolysis on cell proliferation in lung squamous cell carcinoma cell lines and to explore the potential of targeting glutaminolysis as an anticancer strategy. Materials and Methods: Glutamine (Gln) dependence was assessed in six lung squamous cell carcinoma cell lines. Cell proliferation, mammalian target of rapamycin complex 1 (mTORC1) activity and the induction of autophagy were assessed after inhibition of glutaminolysis via Gln depletion or glutaminase (GLS) inhibition. Results: Five of six lung squamous cell carcinoma cell lines exhibited glutamine- dependence. The extent of dependence was correlated with the mRNA levels of GLS1/GLS2. Inhibition of glutaminolysis inhibited cell proliferation by down-regulating of mTORC1 signaling and inducing autophagy in Gln-dependent lung squamous cell carcinoma cell lines. Conclusion: Targeting glutaminolysis may represent a potential therapeutic strategy for the treatment of Gln-dependent lung squamous cell carcinomas.

    DOI: 10.21873/anticanres.11191

    Web of Science

    researchmap

  • Myelosuppression by chemotherapy in obese patients with gynecological cancers 査読

    Kensuke Kamimura, Yoshifumi Matsumoto, Qiliang Zhou, Masato Moriyama, Yasuo Saijo

    CANCER CHEMOTHERAPY AND PHARMACOLOGY   78 ( 3 )   633 - 641   2016年9月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:SPRINGER  

    The American Society of Clinical Oncology provides clinical practice guidelines for appropriate cytotoxic chemotherapy dosing for obese adult patients with cancer. The panel recommends that actual body weight should be used when selecting cytotoxic chemotherapy doses regardless of obesity status. However, there have been no reports regarding the appropriate cytotoxic chemotherapy dosing for obese Japanese patients with cancer.
    We collected data from 216 gynecological cancer patients who were treated with at least one course of a paclitaxel and carboplatin (TC) regimen or a docetaxel and carboplatin (DC) regimen at Niigata University Medical and Dental Hospital from July 2006 to April 2014. Patients were divided into three groups according to body mass index (BMI): obese (BMI aeyen 25), normal (BMI 18.5-24.9), and underweight (BMI &lt; 18.5), as defined by the Japan Society for the Study of Obesity. We analyzed hematological toxicities by full weight-based chemotherapy in each group.
    The rates of grade 3/4 leukocytopenia, neutropenia, and thrombocytopenia were not significantly different among the three BMI groups on all patient analyses. For the TC regimen, the obese and normal groups had significantly lower leukocytopenia (grade 3/4) rates than did the underweight group. Also, significant positive correlations between BMI and the nadirs of leukocytes, neutrophils, platelets, and hemoglobin were observed. For the DC regimen, no significant difference was observed among the BMI groups and the rate of grade 3/4 hematological toxicities.
    We did not observe stronger myelosuppression in obese cancer patients compared with non-obese cancer patients. Therefore, the cytotoxic chemotherapy dose should be calculated by the actual body weight and unnecessary dose reduction should be avoided.

    DOI: 10.1007/s00280-016-3119-2

    Web of Science

    researchmap

  • A case of pancreatic neuroendocrine tumors 査読

    Moriyama Masato, Matsumoto Yoshifumi, Zhou Qiliang, Yamana Kanako, Ikeda Yohei, Ayukawa Fumio, Abe Eisuke, Sato Seijiro, Takano Kabuto, Kaidu Motoki, Aoyama Hidefumi, Saijo Yasuo

    INTERNATIONAL CANCER CONFERENCE JOURNAL   5 ( 1 )   1 - 4   2016年1月

  • A phase II study of erlotinib monotherapy in pre-treated non-small cell lung cancer without EGFR gene mutation who have never/light smoking history: Re-evaluation of EGFR gene status (NEJ006/TCOG0903) 査読

    Yoshifumi Matsumoto, Makoto Maemondo, Yoshiki Ishii, Koichi Okudera, Yoshiki Demura, Kei Takamura, Kunihiko Kobayashi, Naoto Morikawa, Akihiko Gemma, Osamu Ishimoto, Kazuhiro Usui, Masao Harada, Satoru Miura, Yuka Fujita, Ikuro Sato, Yasuo Saijo

    LUNG CANCER   86 ( 2 )   195 - 200   2014年11月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:ELSEVIER IRELAND LTD  

    Objectives: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors are particularly effective in non-small cell lung cancer (NSCLC) patients harboring active EGFR mutations. However, some studies have reported survival benefits in NSCLC patients with wild-type EGFR upon erlotinib treatment. This trial was conducted to evaluate the efficacy of erlotinib monotherapy and investigate the predictive values of several biomarkers.
    Patients and methods: Patients with previously treated NSCLC but without EGFR gene mutations that had never or light smoked were eligible for this study. Gene status screening was performed using the PNA-LNA PCR clamp method. Erlotinib was administered until disease progression or unacceptable toxicities occurred. EGFR gene status was re-evaluated using the fragment method to detect exon 19 deletions and the Cycleave-PCR method to detect point mutations. Expression of hepatocyte growth factor (HGF), Met, and thymidylate synthase (TS) were evaluated using immunohistochemistry.
    Results: Forty-seven patients were enrolled in the study between March 2010 and November 2011. Objective response rate (ORR) and disease control rate (DCR) were 15.2% and 41.3%. Re-evaluations for EGFR gene were performed in 32 tumor samples. EGFR gene mutations were found in eight samples (5:exon 19 deletion, 2:G719X, 1:L858R). Six patients had PR and two had SD among these eight patients. A total of 24 patients were confirmed as wild-type EGFR using different methods. ORR and DCR were 4.2% and 41.7%. The median progression free survival (PFS) and median survival times were 2.0 and 6.0 months, respectively. Patients with tumors expressing HGF showed shorter PFS but not MET or TS.
    Conclusions: Re-examination of EGFR gene status using different detecting method or different sample should be considered to grasp a chance of erlotinib treatment after first line treatment. In confirmed EGFR wild NSCLC, negative HGF staining could be a biomarker for longer PFS by erlotonib treatment. (C) 2014 Elsevier Ireland Ltd. All rights reserved.

    DOI: 10.1016/j.lungcan.2014.08.019

    Web of Science

    researchmap

  • A phase II study of erlotinib monotherapy in pre-treated non-small cell lung cancer without EGFR gene mutation who have never/light smoking history: Re-evaluation of EGFR gene status (NEJ006/TCOG0903) 査読

    Yoshifumi Matsumoto, Makoto Maemondo, Yoshiki Ishii, Koichi Okudera, Yoshiki Demura, Kei Takamura, Kunihiko Kobayashi, Naoto Morikawa, Akihiko Gemma, Osamu Ishimoto, Kazuhiro Usui, Masao Harada, Satoru Miura, Yuka Fujita, Ikuro Sato, Yasuo Saijo

    LUNG CANCER   86 ( 2 )   195 - 200   2014年11月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:ELSEVIER IRELAND LTD  

    Objectives: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors are particularly effective in non-small cell lung cancer (NSCLC) patients harboring active EGFR mutations. However, some studies have reported survival benefits in NSCLC patients with wild-type EGFR upon erlotinib treatment. This trial was conducted to evaluate the efficacy of erlotinib monotherapy and investigate the predictive values of several biomarkers.
    Patients and methods: Patients with previously treated NSCLC but without EGFR gene mutations that had never or light smoked were eligible for this study. Gene status screening was performed using the PNA-LNA PCR clamp method. Erlotinib was administered until disease progression or unacceptable toxicities occurred. EGFR gene status was re-evaluated using the fragment method to detect exon 19 deletions and the Cycleave-PCR method to detect point mutations. Expression of hepatocyte growth factor (HGF), Met, and thymidylate synthase (TS) were evaluated using immunohistochemistry.
    Results: Forty-seven patients were enrolled in the study between March 2010 and November 2011. Objective response rate (ORR) and disease control rate (DCR) were 15.2% and 41.3%. Re-evaluations for EGFR gene were performed in 32 tumor samples. EGFR gene mutations were found in eight samples (5:exon 19 deletion, 2:G719X, 1:L858R). Six patients had PR and two had SD among these eight patients. A total of 24 patients were confirmed as wild-type EGFR using different methods. ORR and DCR were 4.2% and 41.7%. The median progression free survival (PFS) and median survival times were 2.0 and 6.0 months, respectively. Patients with tumors expressing HGF showed shorter PFS but not MET or TS.
    Conclusions: Re-examination of EGFR gene status using different detecting method or different sample should be considered to grasp a chance of erlotinib treatment after first line treatment. In confirmed EGFR wild NSCLC, negative HGF staining could be a biomarker for longer PFS by erlotonib treatment. (C) 2014 Elsevier Ireland Ltd. All rights reserved.

    DOI: 10.1016/j.lungcan.2014.08.019

    Web of Science

    researchmap

  • Differentiation of Mouse Induced Pluripotent Stem Cells Into Alveolar Epithelial Cells In Vitro for Use In Vivo 査読

    Qiliang Zhou, Xulu Ye, Ruowen Sun, Yoshifumi Matsumoto, Masato Moriyama, Yoshiya Asano, Yoichi Ajioka, Yasuo Saijo

    STEM CELLS TRANSLATIONAL MEDICINE   3 ( 6 )   675 - 685   2014年6月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:ALPHAMED PRESS  

    Alveolar epithelial cells (AECs) differentiated from induced pluripotent stem cells (iPSCs) represent new opportunities in lung tissue engineering and cell therapy. In this study, we modified a two-step protocol for embryonic stem cells that resulted in a yield of similar to 9% surfactant protein C (SPC)(+) alveolar epithelial type II (AEC II) cells from mouse iPSCs in a 12-day period. The differentiated iPSCs showed morphological characteristics similar to those of AEC II cells. When differentiated iPSCs were seeded and cultured in a decellularized mouse lung scaffold, the cells reformed an alveolar structure and expressed SPC or T1 alpha protein (markers of AEC II or AEC I cells, respectively). Finally, the differentiated iPSCs were instilled intratracheally into a bleomycin-induced mouse acute lung injury model. The transplanted cells integrated into the lung alveolar structure and expressed SPC and T1 alpha. Significantly reduced lung inflammation and decreased collagen deposition were observed following differentiated iPSC transplantation. In conclusion, we report a simple and rapid protocol for in vitro differentiation of mouse iPSCs into AECs. Differentiated iPSCs show potential for regenerating three-dimensional alveolar lung structure and can be used to abrogate lung injury.

    DOI: 10.5966/sctm.2013-0142

    Web of Science

    researchmap

  • Sequential irinotecan hydrochloride/S-1 for S-1-resistant inoperable gastric cancer: A feasibility study 査読

    Takenori Takahata, Jugoh Itoh, Taroh Satoh, Atsush Ishiguro, Yoshifumi Matsumoto, Satoshi Tanaka, Soh Saitoh, Hiroshi Tohno, Shinsaku Fukuda, Yasuo Saijo, Yuh Sakata

    ONCOLOGY LETTERS   3 ( 1 )   89 - 93   2012年1月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:SPANDIDOS PUBL LTD  

    Irinotecan hydrochloride (CPT-11) is reported to be involved in the downregulation of thymidylate synthase (TS), a target molecule of 5-fluorouracil (5-FU) and oral fluoropyrimidine S-1. Therefore, we hypothesized that a preceding administration of CPT-11 against S-1-resistant tumors may recover sensitivity to S-1. To this end, we planned a S-1/CPT-11 sequential therapy as a feasibility study in S-1-refractory gastric cancer patients. In the first course, CPT-11 was administered intravenously at 150 mg/m(2) on days 1 and 15. Subsequently, S-1 was administered orally for 4 weeks from day 29 to 57, followed by a 2-week interval (sequential S-1/CPT-11). When the tumor showed a complete response (CR) or partial response (PR), the same dose of S-1 monotherapy was continued unless progressive disease (PD) was observed. When the response was stable disease (SD), S-1 was administered at the same dose for just 2 weeks (days 1-15), no drug was administered for the following 2 weeks (4-week cycle) and CPT-11 was administered intravenously at 100 mg/m(2) on days I and 15 (concurrent S-1/CPT-11) unless PD was observed. In the case of PD, the study was terminated. The primary endpoint was an antitumor effect and secondary endpoints were median survival time (MST), progression-free survival (PFS), time-to-treatment failure (TTF) and safety. The response rate (RR) following the first course was only 5.9% and the most positive RR was 11.8%. The MST, median TTF and PFS were 381, 69 and 71 days, respectively. Leukocytopenia was observed in more than half of the patients. Since the RR was lower than estimated in an interim analysis, the trial was terminated and the protocol was concluded to be unfeasible.

    DOI: 10.3892/ol.2011.435

    Web of Science

    PubMed

    researchmap

  • Regulation of class II beta-tubulin expression by tumor suppressor p53 protein in mouse melanoma cells in response to Vinca alkaloid. 査読

    Arai K, Matsumoto Y, Nagashima Y, Yagasaki K

    Molecular Cancer Research   4 ( 4 )   247 - 255   2006年6月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1158/1541-7786.MCR-05-0183

    researchmap

▶ 全件表示

MISC

  • 当院におけるがん遺伝子パネル検査の現状

    中野麻恵, 島田能史, 吉原弘祐, 西野幸治, 関根正幸, 齋木琢郎, 松本吉史, 西條康夫, 棗田学, 今井千速, 川島寛之, 木下義晶, 田中花菜, 市川寛, 永橋昌幸, 栗山洋子, 梅津哉, 奧田修二郎, 池内健, 若井俊文

    日本臨床腫瘍学会学術集会(CD-ROM)   18th   2021年

     詳細を見る

  • 緩和ケア提供中の予測できない死亡症例について~急性期病院緩和ケアチーム医の立場から~

    中島真人, 大竹美幸, 柏木夕香, 西村香, 松本吉史, 生駒美穂, 本間英之

    Palliative Care Research (Web)   16 ( Supplement )   2021年

     詳細を見る

  • ダイヤモンド電極を用いた電気化学測定による薬物血中濃度の迅速測定

    齋木琢郎, 齋木琢郎, 緒方元気, 澤村晴志朗, ラズビナ オリガ, 渡邊航太, 加藤里都, 浅井開, 松本吉史, 森山雅人, 西條康夫, 楠原洋之, 栄長泰明, 日比野浩

    日本生理学雑誌(Web)   83 ( 2 )   2021年

     詳細を見る

  • 血漿パゾパニブ濃度の迅速・簡便測定を目指した計測システムの構築

    緒方元気, 齋木琢郎, 齋木琢郎, 澤村晴志朗, RAZVINA Olga, 渡邉航太, 加藤理都, 浅井開, 花輪藍, 松本吉史, 森山雅人, 西條康夫, 楠原洋之, 栄長泰明, 日比野浩

    日本生体医工学会大会プログラム・抄録集(Web)   60th   2021年

     詳細を見る

  • 免疫チェックポイント薬が著効したMSI-H原発不明がんの1例

    齊木琢朗, 松本吉史, ZHOU Qiliang, 佐々木健太, 森山雅人, 坂井由紀, 西條康夫

    新潟医学会雑誌   134 ( 6 )   2020年

     詳細を見る

  • がん関連血栓塞栓症の早期診断と治療効果判定に有用な臨床検査系の確立

    森山雅人, 松田将門, 小宮山豊, 鈴木健史, 末武司, 佐々木健太, 齋木琢郎, 周啓亮, 松本吉史, 西條康夫

    臨床病理   67   250   2019年10月

     詳細を見る

    記述言語:日本語  

    J-GLOBAL

    researchmap

  • 胚盤胞補完法とES細胞を用いたマウス生体内における肺臓器再生

    冉慶松, 周啓亮, 北原哲彦, 叶許緑, 佐々木健太, 齋木琢郎, 松本吉史, 森山雅人, 泰江章博, 阿部学, 味岡洋一, 笹岡俊邦, 西條康夫

    日本再生医療学会総会(Web)   18th   ROMBUNNO.O‐37‐6 (WEB ONLY)   2019年

     詳細を見る

    記述言語:日本語  

    J-GLOBAL

    researchmap

  • 緩和ケア個別栄養食事管理加算算定の実態報告

    曽根あずさ, 丸山由美子, 澁澤幸子, 磯貝和也, 上路拓美, 三上剛明, 松本吉史, 村山稔子, 生駒美穂

    日本病態栄養学会誌(Web)   22 ( Supplement )   2019年

     詳細を見る

  • 乳癌手術24年後に消化管,リンパ節,皮膚,骨に多発転移をきたした1例

    大脇崇史, 橋本哲, 岩澤貴宏, 水澤健, 五十嵐聡, 上村博輝, 高村昌昭, 周啓亮, 松本吉史, 梅津哉, 寺井崇二

    Endoscopic Forum for Digestive Disease   35 ( 2 )   2019年

     詳細を見る

  • シスプラチンの関与が疑われた即時型アレルギー性肝障害の一症例

    八重樫彩花, 吉田謙介, 島田泉, 鈴木直人, ZHOU Qiliang, 松本吉史, 森山雅人, 西條康夫, 外山聡

    日本臨床腫瘍学会学術集会(CD-ROM)   16th   ROMBUNNO.P1‐119   2018年

     詳細を見る

    記述言語:日本語  

    J-GLOBAL

    researchmap

  • 当院における後期高齢者の食道癌診療と治療成績

    ZHOU Qiliang, 木村和義, 佐々木健太, 松本吉史, 森山雅人, 西條康夫

    日本臨床腫瘍学会学術集会(CD-ROM)   16th   ROMBUNNO.P3‐202   2018年

     詳細を見る

    記述言語:日本語  

    J-GLOBAL

    researchmap

  • AYA世代におけるがん診療の実態調査

    上村賢介, 上村賢介, 松本吉史, ZHOU Qiliang, 森山雅人, 西條康夫

    日本臨床腫瘍学会学術集会(CD-ROM)   16th   ROMBUNNO.P1‐275   2018年

     詳細を見る

    記述言語:日本語  

    J-GLOBAL

    researchmap

  • 当院での局所進行膵臓癌に対するS‐1併用化学放射線療法について

    松本吉史, 周啓亮, 森山雅人, 滝沢一泰, 若井俊文, 青山英史, 西條康夫

    日本癌治療学会学術集会(Web)   55th   ROMBUNNO.P53‐5 (WEB ONLY) - 5   2017年10月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本癌治療学会  

    J-GLOBAL

    researchmap

  • 当院における局所進行膵臓癌に対するS‐1併用化学放射線療法の検討

    松本吉史, 森山雅人, ZHOU Qiliang, 西條康夫

    日本臨床腫瘍学会学術集会(CD-ROM)   15th   ROMBUNNO.P1‐116   2017年

     詳細を見る

    記述言語:日本語  

    J-GLOBAL

    researchmap

  • 当科におけるレンバチニブ治療を施行した進行期甲状腺がん5例の検討

    ZHOU Qiliang, 松本吉史, 森山雅人, 西條康夫

    日本臨床腫瘍学会学術集会(CD-ROM)   15th   ROMBUNNO.O2‐10‐2   2017年

     詳細を見る

    記述言語:日本語  

    J-GLOBAL

    researchmap

  • 生体由来気管スキャフォールドとiPS細胞を用いた気管再生の試み

    周啓亮, 叶許緑, 松本吉史, 森山雅人, 味岡洋一, 西條康夫

    再生医療   15   200   2016年2月

     詳細を見る

    記述言語:日本語  

    J-GLOBAL

    researchmap

  • 日本人肥満がん患者に対する実体重に基づく細胞障害性抗がん剤投与量による血液毒性

    上村賢介, 上村賢介, 森山雅人, 松本吉史, 周啓亮, 西條康夫

    日本臨床腫瘍学会学術集会(CD-ROM)   14th   ROMBUNNO.P1‐187   2016年

     詳細を見る

    記述言語:日本語  

    J-GLOBAL

    researchmap

  • 実体重に基づく細胞障害性抗がん剤投与量が日本人肥満がん患者の血液毒性に与える影響~レジメンによる比較検討~

    上村賢介, 上村賢介, 森山雅人, 松本吉史, 周啓亮, 西條康夫

    日本医療薬学会年会講演要旨集(Web)   26   2016年

     詳細を見る

  • 妊娠を契機に診断されたUpshaw-Schulman症候群症例における第二子妊娠の周産期管理

    森山 雅人, 玉木 悦子, 松本 雅則, 石西 綾美, 松本 吉史, 冨永 麻理恵, 工藤 理沙, 安達 聡介, 生野 寿史, 高桑 好一, 宮腰 淑子, 小堺 貴司, 小林 弘典, 牛木 隆志, 柴崎 康彦, 増子 正義, 瀧澤 淳, 成田 美和子, 曽根 博仁, 西條 康夫

    日本血栓止血学会誌   26 ( 2 )   193 - 193   2015年4月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本血栓止血学会  

    researchmap

  • Erdheim‐Chester病に対してIFN‐αが効果的であった一例

    森山雅人, 松本吉史, 永橋昌幸, ZHOU Qi Liang, 遠藤麻巳子, 高井千夏, 渡辺博文, 成田一衛, 西條康夫

    日本臨床腫瘍学会学術集会(CD-ROM)   13th   ROMBUNNO.P1-2-63   2015年

     詳細を見る

    記述言語:日本語  

    J-GLOBAL

    researchmap

  • がん薬物療法における肥満患者に対する薬剤適正投与量についての検討

    上村賢介, 上村賢介, 森山雅人, 松本吉史, 周けい亮, 西條康夫

    日本臨床腫瘍学会学術集会(CD-ROM)   13th   ROMBUNNO.P3-3-6   2015年

     詳細を見る

    記述言語:日本語  

    J-GLOBAL

    researchmap

  • 新潟大学医歯学総合病院におけるキャンサーボードの概要と現状

    森山雅人, 松本吉史, 白戸亨, 三星美奈子, 海津元樹, 青山英史, 西條康夫

    日本臨床腫瘍学会学術集会(CD-ROM)   12th   ROMBUNNO.O2-16-2   2014年

     詳細を見る

    記述言語:日本語  

    J-GLOBAL

    researchmap

  • マウスiPS細胞における肺上皮細胞への分化誘導

    XHOU Qiliang, YE Xulu, SUN Ruowen, 松本吉史, 浅野義哉, 西條康夫

    再生医療   12   2013年

     詳細を見る

▶ 全件表示